[Form 4] Accenture PLC Insider Trading Activity
Rhea-AI Filing Summary
Arun Sarin, a director of Accenture plc (ticker ACN), reported an acquisition on 08/15/2025 of 8,473 Class A ordinary shares via grant (Transaction Code A) of restricted share units. The grant was made pursuant to anti-dilution provisions tied to previously awarded RSUs to reflect Accenture's payment of a cash dividend. The reported price per share is $247.57, and the amount beneficially owned following the transaction is listed as 8,473 shares. The Form 4 was signed on behalf of Mr. Sarin by an attorney-in-fact on 08/18/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director received RSUs adjusted for a cash dividend, a routine anti-dilution mechanic that preserves economic value of prior awards.
The filing documents a nonsale acquisition of 8,473 Class A ordinary shares by a sitting director through adjustment of previously granted restricted share units. This is described as an anti-dilution grant tied to a dividend payment, which is a common administrative action to preserve the economic interest of equity awards when dividends are paid in cash. There is no disclosure of option exercises, cash outlay by the director, or changes to director status. For governance review, this is procedural and does not signal a change in control, compensation policy, or director independence.
TL;DR: Form 4 shows a standard acquisition of shares via RSU adjustment; transaction code and amounts are clearly reported.
The Form 4 reports Transaction Code A for an acquisition of 8,473 shares at a reported price of $247.57, with the filename indicating these are non-derivative securities converted from RSUs under anti-dilution provisions. This is a regulatory disclosure of insider holdings and meets Section 16 reporting requirements. No dispositions, derivative positions, or additional compensatory arrangements beyond the anti-dilution note are disclosed. Impact on float or ownership percentage is not provided in the filing.